Sort
85,873 grants matching “alzheimers”
ITM 2.0: Advancing Translational Science in Metropolitan Chicago
$5,837,630Julian Solway · University Of Chicago · UL1 · FY2017 · TR
Wisconsin Registry for Alzheimer's Prevention
$5,831,891Sterling C Johnson · University Of Wisconsin-Madison · R01 · FY2024 · AG
Metabolic Signatures Underlying Vascular Risk Factors for Alzheimer-type Dementias
$5,802,396Rima F Kaddurah-Daouk · Duke University · RF1 · FY2015 · AG
Alzheimer's Disease Cooperative Study (ADCS)
$5,798,687Paul S. Aisen · University Of California, San Diego · U01 · FY2011 · AG
Life's end Benefits of CannaBidol and TetrahYdrocannabinol (LiBBY) Trial
$5,795,813Jacobo E. Mintzer · Medical University Of South Carolina · R01 · FY2020 · AG
Plasma brain-derived tau: a novel Alzheimerâs disease-type neurodegeneration biomarker with potential to complete the AT(N) scheme in blood
$5,794,471Thomas K Karikari · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · AG
Examining Effects of Intensive BP Control on MCI/Dementia and Plasma Biomarker Trajectories by AD Pathology: Elucidating neuroprotective effects in the racially and ethnically diverse SPRINT trial
$5,789,766Adam P Bress · Utah State Higher Education System--University Of Utah · R01 · FY2025 · AG
Sex and APOE genotype interact to alter immune regulated metabolism in AD
$5,785,588Carol A Colton · Duke University · RF1 · FY2019 · AG
Alzheimer's Disease Cooperative Study (ADCS)
$5,782,372David Salmon · University Of California, San Diego · U01 · FY2006 · AG
ITM 2.0: Advancing Translational Science in Metropolitan Chicago
$5,775,630Julian Solway · University Of Chicago · UL1 · FY2019 · TR
ITM 2.0: Advancing Translational Science in Metropolitan Chicago
$5,775,630Julian Solway · University Of Chicago · UL1 · FY2018 · TR
ITM 2.0: Advancing Translational Science in Metropolitan Chicago
$5,775,630Julian Solway · University Of Chicago · UL1 · FY2020 · TR
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease
$5,774,586Anthony O Caggiano · Cognition Therapeutics, Inc. · R01 · FY2020 · AG
IUSM Alzheimer's Disease Drug Discovery Center
$5,774,436Alan D. Palkowitz · Indiana University Indianapolis · U54 · FY2019 · AG
Study of Latinos-Investigation of Neurocognitive Aging-Alzheimer's disease
$5,763,512Hector M Gonzalez · University Of California, San Diego · R01 · FY2023 · AG
ALZHEIMERS DISEASE COOPERATIVE STUDY
$5,761,712University Of California San Diego · U01 · FY2000 · AG
National Longitudinal Study of Adolescent to Adult Health (Add Health): Wave VI Core Project
$5,759,696Robert A Hummer · Univ Of North Carolina Chapel Hill · U01 · FY2022 · AG
Dallas Lifespan Brain Study-Wave 3: Neurodegeneration & Resilience in Cognition
$5,755,201Denise Cortis Park · University Of Texas Dallas · RF1 · FY2017 · AG
Alzheimer's Prevention Initiative ADAD Colombia Trial
$5,754,078Eric M Reiman · Banner Health · R01 · FY2022 · AG
Dominantly Inherited Alzheimer Network
$5,747,863Randall J Bateman · Washington University · U19 · FY2020 · AG
Biomarkers of Alzheimer's Disease in Adults with Down Syndrome
$5,747,597Nicole Schupf · Columbia University Health Sciences · U01 · FY2019 · AG
National Longitudinal Study of Adolescent to Adult Health (Add Health): Wave VI Cognition and Early Risk Factors for Dementia Project
$5,737,400Robert A Hummer · Univ Of North Carolina Chapel Hill · U01 · FY2024 · AG
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer's Disease
$5,735,586Susan M Catalano · Cognition Therapeutics, Inc. · R01 · FY2019 · AG
Disease Model Development and Phenotyping Project
$5,733,814Kim Green · University Of California-Irvine · U54 · FY2024 · AG
Biospecimen Core
$5,709,490Bharat Thyagarajan · Washington University · U19 · FY2020 · AG